Pronova BioPharma ASA (OSL:PRON) Study Demonstrating Lovaza/Omacor Co-administered With Atorvastatin Reduces Non-HDL Cholesterol To Be Presented At AHA
Pronova BioPharma ASA (OSL:PRON) 11 November, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that a study to be presented at the American Heart Association Scientific Sessions in New Orleans, USA, shows that Lovaza/Omacor co-administered with atorvastatin significantly improves non-HDL cholesterol and triglycerides compared with atorvastatin alone. An abstract of the study was published on the AHA's conference website http://www.abstractsonline.com/plan/start.aspx?mkey=%7BD78A4520%2D4797%2D409B%2DBF84%2D2F89D1773D57%7D .